synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
When used during pregnancy, the majority of adverse events caused by acupuncture were mild and transient, with few serious adverse events. The most frequent mild adverse event was needling or unspecified pain, followed by bleeding. Although two deaths (one stillbirth and one neonatal death) were reported, there was a lack of acupuncture-associated maternal mortality. Limiting the evidence as certain, probable or possible in the causality evaluation, the estimated incidence of adverse events following acupuncture in pregnant women was 131 per 10,000. Although acupuncture is not contraindicated in pregnant women, some specific acupuncture points are particularly sensitive to needle insertion; these spots, as well as the abdominal region, should be avoided during pregnancy.
The Journal of Separation Science is a biweekly peer-reviewed scientific journal covering analytical chemistry. It was established in 1978 as the Journal of High Resolution Chromatography & Chromatography Communications: HRC & CC. In 1989, it was renamed the Journal of High Resolution Chromatography. It obtained its current name in 2001, when it also absorbed the preexisting Journal of Microcolumn Separations, which had been established in 1989. It is an organ of the European Society for Separation Science and the California Separation Science Society. The editor-in-chief is František Švec (Charles University). According to the Journal Citation Reports, the journal has a 2020 impact factor of 3.645, ranking it 25th out of 83 journals in the category "Chemistry, Analytical".
== Match-fixing scandals == Ten of the twelve members of the gold medal-winning Spanish basketball team at the 2000 Summer Paralympics were revealed to have no disability. Fresno Case scandal (2004) – an attempt to rig a vote to prevent the Catalan rink hockey team from being accepted into international competition. Melbourne Football Club tanking scandal (2009) – allegations arose that the club deliberately lost matches in 2009 so that it would put itself into a position whereby they would secure a priority draft pick at that year's draft. In 2011, snooker player John Higgins was accused of accepting bribery in order to lose frames purposefully. Higgins denied any accusations of match-fixing and bribery, however, he was found guilty of accepting bribery while there was no evidence for him match-fixing. "World number one John Higgins has been suspended from all future tournaments after reportedly agreeing to take a £261,000 bribe to lose frames." Match fixing in tennis 1964 British football match-fixing scandal 1971 Bundesliga scandal Match-fixing investigations of Norwegian Second Division Match fixing in English football Match fixing in Romanian football
Sources: en.wikipedia.org
== Chemistry == Pregabalin is a GABA analogue that is a 3-substituted derivative as well as a γ-amino acid. Because of its chemical and pharmacological similarities to gabapentin, it is sometimes called a gabapentinoid drug. Specifically, pregabalin is (S)-(+)-3-isobutyl-GABA. Pregabalin also closely resembles the α-amino acids L-leucine and L-isoleucine, and this may be of greater relevance in relation to its pharmacodynamics than its structural similarity to GABA.
== Medical uses == Pegulicianine is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.
The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor, AMPAR, or quisqualate receptor) is a nonselective ionotropic glutamate receptor (iGluR) that mediates fast excitatory neurotransmission in the central nervous system (CNS).
== Etymology == The term "botany" comes from the Ancient Greek word botanē (βοτάνη) meaning "pasture", "herbs" "grass", or "fodder"; Botanē is in turn derived from boskein (Greek: βόσκειν), "to feed" or "to graze". Traditionally, botany has also included the study of fungi and algae by mycologists and phycologists respectively, with the study of these three groups of organisms remaining within the sphere of interest of the International Botanical Congress.
Sources: en.wikipedia.org
Following the excision of the foreskin, the surgical wound undergoes the standard physiological phases of healing: hemostasis, inflammation, cellular proliferation, and tissue remodeling. Because circumcision severs the dense network of superficial blood vessels and lymphatic channels within the prepuce and dartos fascia, normal fluid drainage is temporarily interrupted. This disruption to the lymphatic system typically results in localized post-operative edema (swelling) around the incision line and the remaining mucosal collar. During the proliferative and remodeling phases of recovery, the body undergoes angiogenesis (the formation of new blood vessels) and lymphangiogenesis. The vascular and lymphatic networks are gradually reconstructed to establish new collateral drainage pathways across the surgical boundary. As this structural tissue remodeling matures over the weeks following the procedure, the post-operative swelling resolves and physiological fluid balance is restored to the penile skin.
The two substrates of this enzyme are glycerol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are glycerone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is glycerol:NADP+ 2-oxidoreductase (glycerone-forming). Other names in common use include dihydroxyacetone reductase, dihydroxyacetone (reduced nicotinamide adenine dinucleotide, phosphate) reductase, dihydroxyacetone reductase (NADPH), DHA oxidoreductase, and glycerol 2-dehydrogenase (NADP+). This enzyme participates in glycerolipid metabolism.
=== Laboratory methods === Curtius and Thiele developed another production process, where a nitrite ester is converted to sodium azide using hydrazine. This method is suited for laboratory preparation of sodium azide:
CYP2D6 metabolizer phenotypes do not modify psilocin exposure in humans, suggesting that CYP2D6 is not critically involved in psilocin metabolism and is unlikely to result in interindividual differences in psilocin kinetics or effects. Psilocybin and psilocin might inhibit CYP3A4 and CYP2A6 to some extent, respectively.
=== Casting === In February 2025, Jessica Lange, who starred in the first four seasons and briefly appeared in the eight season in 2018, answered a question about her potential return for the thirteenth season: "Oh Christ, no. I mean, I haven't done it for more than 10 years, 12 years, so, no, I'm not doing it." Murphy revealed that Lange was the first person he turned to about the return and she agreed under the condition she would have a musical number. Subsequently, he turned to Sarah Paulson and Evan Peters, who agreed instantly. They both last appeared in the tenth season in 2021. In October 2025, Lange, Paulson, Peters, Emma Roberts, Billie Lourd, Kathy Bates, Angela Bassett, Leslie Grossman, Jessica Lange, and Gabourey Sidibe were all confirmed to return for the thirteenth season, along with the newcomer Ariana Grande. Bates, Bassett and Sibide last appeared in the eight season in 2018. Bates revealed that she would have only one day of filming. In February 2026, John Waters joined the cast, while Joey Pollari joined in April, and Alex Consani and Paul Anthony Kelly joined in May. John Carroll Lynch and Matt Fraser were also confirmed to reprise their roles from Freak Show, with Mena Suvari and Berto Colón also joining the cast. In July, Frances Conroy was confirmed to reprise her role from Coven, with Avantika, Grace Dumdaw, Cara Delevingne, and Charlie Carver also joining the cast. In July 2026, it was reported that Grande dropped out due to scheduling conflicts with the season's production schedule and her Eternal Sunshine Tour.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.